Journal of diabetes investigation 2017 10 13() doi 10.1111/jdi.12760
To evaluate whether there is disparity of the efficacy and all cause mortality and other adverse effects between Asian and non-Asian patients with SGLT2 inhibitors treatment.
Randomized clinical trials publicly available before January 2017, comparing SGLT2 inhibitors treatment with placebo in type 2 diabetes patients were identified. The registration number of this meta-analysis is CRD42016047666. The association between treatment and outcomes was estimated by computing the weighted mean difference (WMD) for HbA1C level, blood pressure level, lipid profile levels and body weight and the odds ratios (ORs) for adverse events.
In Asians 17 trials were included and in non-Asians 39 trials were included. Comparison of the HbA1c decreases corrected by placebo between Asian and non-Asian patients indicated that there was a non-significant difference of 0.05% between groups (p>0.05). Comparisons of the body weight changes, blood pressure changes corrected by placebo between Asian and non-Asian did not show significant difference between groups (p>0.05). The risk of all cause mortality was not increased when compared with placebo both in Asian and non-Asian population, and the risk of genital infection in Asian and non-Asian population were both significant increased.
Overall, according to this meta-analysis, comparison of the efficacy in SGLT2 inhibitors treatment between Asian and non-Asian type 2 diabetes patients indicated no significant difference in HbA1c reduction and body weight reduction. Moreover, no disparity was found in the risk of all cause mortality or hypoglycemia in SGLT2 inhibitors treatment between Asian and non-Asian patients. This article is protected by copyright. All rights reserved.